B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
J. Griss, W. Bauer, C. Wagner, M. Maurer-Granofszky, M. Simon, M. Chen, P. Steinberger, K. Grabmeier-Pfistershammer, F. Roka, T. Penz, C. Bock, G. Zhang, M. Herlyn, K. Glatz, H. Laubli, K. D. Mertz, P. Petzelbauer, T. Wiesner, M. Hartl, W. Pickl, R. Somasundaram, S. N. Wagner
Abstract
Tumor associated inflammation is one of important predictors of response to immune checkpoint blockade. Understanding molecular processes that regulate tumor inflammation is key to improve the efficacy of checkpoint blockade. Established mechanisms that underlie therapy response and resistance have centered on anti-tumor T cell responses.\n\nWe show that tumor-associated B cells are vital to T cell functions. They promote recruitment of CD8+ T cells through plasmablast-like cells with expression of pro- and anti-inflammatory factors. Plasmablast-like cells are associated with improved survival of patients with metastatic melanoma and their response to checkpoint blockade. Plasmablast-like B cells express chemokines for T cell-attraction. Depletion of tumor-associated B cells by anti-CD20 immunotherapy of metastatic melanoma patients causes a remarkable decrease in tumor CD8+ T cells. These findings indicate that tumor-associated B cells orchestrate and sustain tumor inflammation, recruit CD8+ T effector cells and are key to therapeutic response and patients overall survival.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Melanoma Response to Immunotherapy is regulated by B Cell-Derived Extracellular Vesicles
Ala’a Al Hrout, Agshin Balayev, … Richard Chahwan·Science AdvancesPeer-reviewed·Oct 8, 2025
- Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Matthew P. Zimmerman, Amy Y. Huang, … Brian C. Miller·bioRxiv·Feb 8, 2026
- Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
A. Gangaev, E. A. Rozeman, … P. Kvistborg·bioRxiv·Dec 15, 2020
- CD244 regulates both innate and adaptive immune axes in melanoma by inhibiting autophagy-mediated M1 macrophage maturation
- NK cells contribute to resistance to anti-PD1 therapy in immune-excluded melanomas
Ewout Landeloos, Joanna Poźniak, … Jean‐Christophe Marine·bioRxiv·Dec 14, 2023
- Comprehensive immune profiling of melanoma-draining lymph nodes identifies plasmacytoid dendritic cells as new biomarker for PD-L1 blockade
Emma Reynaud, Sonya Belherazem, … Lothar C. Dieterich·bioRxiv·Aug 22, 2025